The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis

Tara M. Mackay, F. Jasmijn Smits, Daphne Roos, Bert A. Bonsing, Koop Bosscha, Olivier R. Busch, Geert-Jan Creemers, Ronald M. van Dam, Casper H. J. van Eijck, Michael F. Gerhards, Jan Willem B. de Groot, Bas Groot Koerkamp, Nadia Haj Mohammad, Erwin van der Harst, Ignace H. J. T. de Hingh, Marjolein Y. Homs, Geert Kazemier, Mike S. L. Liem, Vincent E. de Meijer, I. Quintus MolenaarVincent B. Nieuwenhuijs, Hjalmar C. van Santvoort, George P. van der Schelling, Martijn W. J. Stommel, Albert Jan ten Tije, Judith De Vos-Geelen, Fennie Wit, Johanna W. Wilmink, Hanneke W. M. van Laarhoven, Marc G. Besselink*, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Web of Science)
Original languageEnglish
Pages (from-to)233-240
Number of pages8
JournalHPB
Volume22
Issue number2
DOIs
Publication statusPublished - Feb 2020

Keywords

  • INTERNATIONAL STUDY-GROUP
  • POSTOPERATIVE COMPLICATIONS
  • SURGICAL COMPLICATIONS
  • OPEN-LABEL
  • CANCER
  • SURGERY
  • PANCREATICODUODENECTOMY
  • GEMCITABINE
  • DEFINITION
  • MORTALITY

Cite this